Price of key drug rose by 12,000 per cent, British probe finds

Authorities in Britain and US step up pressure on drug firms over prices

16th December, 2016
CMA crackdown on drug pricing. Pic:iStock

In Britain, the country’s main competition body, the Competition and Markets Authority (CMA) has been cracking down on excessive prices being charged to the country’s National Health Service (NHS).

This morning, it announced the provisional findings of an investigation into the price charged by a company called Actavis UK for hydrocortisone tablets, which are used to treat life-threatening conditions such as Addison’s disease.

The CMA said Actavis UK had...

Subscribe from just €1 for the first month!

Currency

What's Included

With any subscription you will have access to

  • 971569B3-2C5E-4C45-B798-CEADE16987A8

    Unlimited multi-device access to our iPad, iPhone and Android Apps

  • 099C8662-C57C-42F2-9426-F2F90DF17C8F

    Unlimited access to our eReader library

  • 198AE43B-B9CF-4892-8769-D63C2104BA08

    Exclusive daily insight and opinion seven days a week

  • D8F37B78-25E4-4E4A-A376-4F5789B1564A

    Create alerts to never miss a subject that matters to you

  • B15F2521-37CD-4E02-B898-730A20D39F7F

    Get access to exclusive offers for subscribers on gifts and experiences

  • A564FE02-1AB8-4579-AF9D-BA32A2E5ACA7

    Get content from Business Post, Business Post Magazines, Connected, Tatler and Food & Wine

Share this post

Related Stories

Editorial: Our inability to agree on a model of healthcare in Ireland is unacceptable

HSE yet to cooperate with Sláintecare business case

Health Daniel Murray 17 hours ago

Healthcare software developers claim they could cut waiting lists by 25%

Health Rachel Lavin 6 days ago

Tony O’Brien: The apparent slow collapse of Sláintecare deserves more than a shrug of the shoulders

Health Tony O'Brien 1 week ago